Nous-209 Efficiently Stimulates Immunity Against Neoantigens in Lynch Syndrome Carriers By Ogkologos - February 3, 2026 90 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase Ib/II study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Nivolumab Plus Low-Dose Ipilimumab Demonstrates Clinical Benefit in First-Line Treatment for... October 20, 2021 FDA Approves Rituximab Plus Chemotherapy for Paediatric Cancer Indications December 10, 2021 How to Stay Healthy After Cancer October 28, 2020 NRG1 Fusion–positive Lung Cancers are Molecularly, Pathologically, and Clinically More Heterogeneous... June 8, 2021 Load more HOT NEWS Sotorasib Shows Promising Activity and Acceptable Safety in Patients with Previously... Trastuzumab Deruxtecan Demonstrates Durable Responses in Patients with Previously Treated HER2-mutated... A urine test for bladder cancer: What’s the latest? Ivosidenib and Azacitidine Combination Shows Significant Clinical Benefit in Patients with...
